GlassScriptPhysician profile
Neha Sirohi
NPI 1689084816
$61,904.26
in general payments reported to CMS, 2019-2025
49 companies · $35K in 2025
The $35K reported for 2025 was more than what 94% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $2,263 · 2021: $3,105 · 2022: $4,593 · 2023: $6,809 · 2024: $9,828 · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $19K · Consulting Fee: $11K · Travel and Lodging: $1,882 · Education: $64.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,873.33 |
| Food and Beverage | $19,019.67 |
| Consulting Fee | $10,557.07 |
| Travel and Lodging | $1,881.92 |
| Education | $64.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24,028.40 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Genzyme Corporation | $9,309.56 | 2020-2025 | |
| Sanofi US Services INC. | $7,175.67 | 2025 | |
| Glaxosmithkline, LLC. | $3,453.15 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Ars Pharmaceuticals Operations, INC. | $2,457.58 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $1,422.01 | 2019-2025 | |
| Optinose US, INC. | $1,094.01 | 2019-2025 | |
| Alk-Abello, INC | $968.81 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Abbvie INC. | $922.41 | 2022-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $905.50 | 2021-2025 | Takhzyro, Hyqvia, Eohilia |
| Regeneron Healthcare Solutions, INC. | $894.46 | 2019-2025 | Dupixent |
| Pfizer INC. | $805.70 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $730.70 | 2023-2025 | Orladeyo |
| Blueprint Medicines Corporation | $628.47 | 2022-2025 | Ayvakit |
| Aimmune Therapeutics, INC. | $572.94 | 2020-2023 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.93 | 2020-2022 | |
| Grifols USA, LLC | $470.00 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Kaleo, INC. | $447.61 | 2019-2024 | Auvi-Q |
| Csl Behring | $442.54 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Genentech USA, INC. | $415.62 | 2019-2025 | Xolair |
| Becton, Dickinson and Company | $406.67 | 2024 | |
| Amneal Pharmaceuticals LLC | $390.00 | 2024 | |
| Halozyme INC | $380.00 | 2024 | |
| Galderma Laboratories, L.P. | $379.78 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $353.79 | 2020-2022 | |
| Lilly USA, LLC | $318.40 | 2024-2025 | Ebglyss |
| Amgen INC. | $309.71 | 2022-2025 | Tezspire |
| Stryker Corporation | $226.49 | 2019-2022 | |
| Leo Pharma INC. | $179.02 | 2022-2023 | Adbry |
| Hikma Pharmaceuticals USA | $150.44 | 2022-2024 | Ryaltris, Kloxxado |
| Dermavant Sciences, INC. | $136.25 | 2023-2024 | Vtama |
| Incyte Corporation | $135.50 | 2022-2025 | Opzelura |
| Aytu Biopharma, INC. | $100.99 | 2024-2025 | Karbinal |
| Ionis Pharmaceuticals, INC. | $90.17 | 2025 | Dawnzera |
| Organon LLC | $85.20 | 2025 | Vtama |
| Adma Biomanufacturing LLC | $83.90 | 2025 | |
| Pharming Healthcare, INC. | $72.90 | 2021-2022 | |
| Cycle Pharmaceuticals INC | $65.79 | 2024-2025 | Sajazir |
| Eyevance Pharmaceuticals LLC | $63.24 | 2020 | |
| Octapharma USA, INC. | $62.98 | 2024-2025 | Panzyga, Cutaquig |
| Horizon Therapeutics Plc | $53.68 | 2021-2022 | |
| Phadia US INC. | $52.45 | 2020-2024 | Immunocap |
| Aerin Medical INC. | $33.66 | 2022-2025 | |
| Invivyd INC | $19.41 | 2025 | Pemgarda |
| Shire North American Group INC | $18.89 | 2019 | |
| Gc Biopharma USA, INC. | $18.39 | 2025 | Alyglo |
| Kyowa Kirin, INC. | $14.95 | 2025 | |
| Merck Sharp & Dohme LLC | $14.47 | 2023 | |
| Bio Products Laboratory USA, INC. | $10.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Sirohi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.